Overview of Dr. Shepherd
Dr. Annemarie Shepherd is a radiation oncologist in Seattle, WA and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 7 years. She is one of 106 doctors at Memorial Sloan Kettering Cancer Center who specialize in Radiation Oncology. She has more than 50 publications and over 500 citings.
Office
1959 NE Pacific St
Seattle, WA 98195
Education & Training
- University of Pennsylvania Health SystemResidency, Radiation Oncology, 2001 - 2015
- University of Pennsylvania Health SystemInternship, Internal Medicine, 2010 - 2011
- Rutgers Robert Wood Johnson Medical SchoolClass of 2010
Certifications & Licensure
- FL State Medical License 2023 - Present
- NY State Medical License 2017 - 2026
- NJ State Medical License 2015 - 2025
- WA State Medical License 2024 - 2025
- OK State Medical License 2020 - 2021
- PA State Medical License 2010 - 2016
- American Board of Radiology Radiation Oncology
Clinical Trials
- A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest Start of enrollment: 2022 Apr 26
Roles: Principal Investigator, Contact
- Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2020 May 07
Roles: Contact, Principal Investigator
- A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma Start of enrollment: 2021 Aug 10
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 12 citationsPre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab.Maria Thor, Annemarie F Shepherd, Isabel Preeshagul, Michael Offin, Daphna Y Gelblum
Radiotherapy and Oncology. 2022-02-01 - 33 citationsRadiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab.Narek Shaverdian, Maria Thor, Annemarie F. Shepherd, Michael Offin, Andrew Jackson
Cancer Medicine. 2020-05-06 - 11 citationsAssociation Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC.Narek Shaverdian, Michael Offin, Annemarie F. Shepherd, Matthew D. Hellmann, Daniel R. Gomez
JTO Clinical and Research Reports. 2021-07-01
Press Mentions
- Prevencio and Memorial Sloan Kettering Cancer Center Data Demonstrates Significant Correlation of AI-Driven HART CVE Blood Test Scores with Development of Adverse Heart Events Following Cancer Radiation TreatmentOctober 27th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: